Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 4 fiscal years.
Financials
Financial year 2025
PHARMATEAM INVEST from Wavre, company number BE0870188780, closed financial year 2025 with a result of € 1,862 after tax. For that financial year PHARMATEAM INVEST recorded revenue of € 630,000 and equity of € -25,432. Compared with financial year 2024, the result moved from € -42,414 to € 1,862. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
€ -25,432
▲ € 1,862 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1,862
▲ still € 42,414 loss in 2024
Profit after tax over the fiscal year.
€ 97,943
▲ 94% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -37,832.
People and assets in 2025
€ 33,312
▼ 36% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 39,629
▼ 33% vs 2024
€ 22,031 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 67,300
▲ 297% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 47 days on average.
€ 29,405
▼ 7% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 842,941 | € 721,568 | € 600,000 | € 630,000 | ▲ 5% |
| Profit after taxes | € 37,266 | € -148,241 | € -42,414 | € 1,862 | ▲ € 44,276 |
| Equity | € 163,362 | € 15,121 | € -27,294 | € -25,432 | ▲ € 1,862 |
| Total debts | € 337,997 | € 148,095 | € 107,856 | € 136,469 | ▲ 27% |
| Cash | € 190,453 | € 86,697 | € 50,571 | € 97,943 | ▲ 94% |
| Land & buildings | € 28,500 | € 28,500 | € 28,500 | € 28,500 | |
| Retained profit | € 150,962 | € 2,721 | € -39,694 | € -37,832 | ▲ € 1,862 |
| Dividend | € 80,000 | € 0 | € 0 | € 0 | |
| Bank debt | € 95,947 | € 77,910 | € 59,147 | € 39,629 | ▼ 33% |
| Balance sheet total | € 1,253,919 | € 1,068,909 | € 1,081,347 | € 1,102,798 | ▲ 2% |
Key figures of PHARMATEAM INVEST, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMATEAM INVEST?
What happened at PHARMATEAM INVEST in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 1,862. Source: NBB ↗
- Start of the company according to the CBE. KBO
- New establishment in Grez-Doiceau. KBO
In short
From € 37,266 profit in 2022 to € 1,862 profit in 2025.
Paid € 22,366 in corporate taxes since 2022.
Best year ever: 2022, with € 37,266 profit.
Paid out € 80,000 in dividends to the owners in total.
A new publication or filing at PHARMATEAM INVEST? We notify you, reason included.
Follow PHARMATEAM INVESTDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMATEAM INVEST is Emmanuelle Servais. Emmanuelle Servais is also behind APOTHEEK DE LINDE, PHARMACENTRE, SOGIPHARMA, PHARMACIES SERVAIS and Pharmacie d’Ohain.
Directors
According to the 2025 annual accounts
Emmanuelle Servais
Director
Also active at: APOTHEEK DE LINDE, PHARMACENTRE, SOGIPHARMA, PHARMACIES SERVAIS, Pharmacie d’Ohain, PHARMACIE DU PRINCE D'ORANGE
Establishments
Establishment units
Physical locations of this company
Chaussée de Namur 5
1300 Wavre
Ruelle des Croix 39
1390 Grez-Doiceau
Active since 23 November 2004
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0870.188.780
- VAT number
- BE 0870.188.780
- Registered office
- Chaussée de Namur 5, 1300 Wavre
- Names & denominations
- PHARMATEAM INVEST
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 25 November 2004
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Adviesbureaus op het gebied van public relations en communicatie
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Public relationsbureaus
Overige adviesbureaus op het gebied van bedrijfsvoering en beheer
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering